Abbott initiates pivotal CROWN-MV trial for Cephea device
The study enrolls 585 patients with mitral valve disease to evaluate safety and efficacy. Early feasibility data will be presented at TCT 2026.
See the latest news and media coverage for Abbott. We track all announcements, press releases, and industry mentions in real time, all in one place.
Global healthcare products and technologies company
abbott.comLast updated
In short: Abbott announced Nutrition spin-off, reported Q3 growth, settled formula claims and won device approvals.
The study enrolls 585 patients with mitral valve disease to evaluate safety and efficacy. Early feasibility data will be presented at TCT 2026.
The Amplatzer Paraclose PVL Occluder is the first US transcatheter device for treating paravalvular leaks without open-heart surgery
The $8.5 billion division will become an independent public company with iconic brands like Ensure and Similac, while Abbott focuses on healthcare technology.
Third-quarter comparable sales grew 7.0%, with adjusted diluted EPS of $1.42. The company announced FDA approvals for new devices and confirmed dividend payments.
Third-quarter sales increased 14.5 percent on a reported basis and 7.0 percent on a comparable...
Abbott CEO Robert Ford explains how LAA and diabetes pressures drove Q3 guidance cuts, and what's ahead for 2027 growth.
Abbott Laboratories said it is spinning off its nutrition business, a division that has been dogged by a baby-formula contamination crisis, shortages and lawsuits in...
A federal judicial panel centralized 49 lawsuits into two manufacturer-specific proceedings, again declining to put all spinal cord stimulator litigation before one judge. The U.S...
Track Abbott and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Abbott and other trending companies.